Prostate cancer

Treatment of prostate cancer

What is prostate cancer

Prostate cancer, or prostate cancer (PC) is a rapidly growing oncological disease of older men, the increase of which, according to some reports, was more than 500% (!) compared to the early 90s. Such a surge, first of all, is associated with the widespread introduction of a program for the early detection of this pathology.

On the other hand, prostate cancer has a clear correlation with age: the risk of developing a malignant tumor in the prostate gland is significantly higher in men over 65 years of age compared to men of 50 years of age. Considering that life expectancy, especially in developed countries, is noticeably increasing, this factor can also be considered the reason for the increase in the incidence of prostate cancer.

Prostate cancer ranks first among all malignant neoplasms in the male population, therefore, today great attention is paid to the treatment of prostate cancer: surgical approaches are being reviewed, minimally invasive techniques for operations on tumors are being developed, radiation therapy is being improved (including contact brachytherapy), new drugs are being developed for drug treatment.

Prostate cancer develops due to mutations in prostate cells. These mutations can cause uncontrolled division and tumor formation.

Causes of prostate cancer

The causes of mutations in cells that cause prostate cancer and other oncological diseases have not yet been fully elucidated. But there are some risk factors that increase the chance of developing a tumor.

The main cause of prostate cancer can be called age. The longer the life expectancy of a man, the longer androgens - male sex hormones - have a stimulating effect on prostate tissue. It is this, according to modern data, that predisposes to the development of a malignant tumor in the prostate, and the system of drug treatment is built on the same theory, the main direction of which is hormone therapy.

The following can also contribute to the appearance and growth of malignant cells in the prostate:

  • overweight;
  • prostatic hyperplasia, chronic prostatitis and other inflammatory diseases and conditions of the prostate;
  • injuries;
  • prostate adenomas;
  • Fatty diet

Heredity plays a big role in the occurrence of prostate cancer. It has been established that a malignant tumor is much more common in men whose closest relatives have also been diagnosed with prostate cancer.

Prostate cancer stages

  • Stage 1 - the tumor is not aggressive, has a small size and is located within the prostate gland;
  • Stage 2 - the tumor is enlarged, but still affects only the tissues of the prostate;
  • Stage 3 - prostate cancer begins to spread beyond the prostate gland and affect the seminal vesicles and other adjacent tissues and organs;
  • Stage 4 - a malignant tumor captures the bladder, affects the lymph nodes and metastasizes to other organs (for example, the lungs) and tissues (bone).

Terminal stage IV prostate cancer is difficult to treat and has a poor prognosis.

Types of prostate cancer

The most common prostate cancer is adenocarcinoma. This tumor develops from the glandular cells of the organ. There are also rarer forms of cancer, such as neuroendocrine, small cell carcinoma, sarcoma, and transitional cell carcinoma of the prostate.

Prevention of prostate cancer

Ways to prevent this oncological disease have not yet been precisely determined. There is evidence that the risk of prostate cancer reduces the use of tomatoes. But this issue has not been sufficiently studied. However, to improve the prognosis and facilitate the treatment of the tumor, regular examination by a urologist helps to detect prostate cancer in the early stages. The most widely available test is the prostate-specific antigen (PSA) test. This is a tumor marker that enters the blood due to damage to the blood vessels of the prostate gland and normally should not exceed 4 ng / ml. Higher values may indicate both a malignant process in this organ and other prostate diseases (for example, adenoma).

Prostate cancer symptoms

Difficulties in early detection of prostate cancer are associated with its asymptomatic course in the early stages. The appearance of clinical signs of the disease, as a rule, indicates a running process. All signs of prostate cancer can be divided into two groups: symptoms of a local tumor and symptoms of metastases. Unfortunately, they are very similar to the symptoms of other diseases of the male genitourinary system.

Patients with prostate cancer may experience the following:

  • difficulty urinating;
  • frequent urination in small portions (especially at night);
  • burning and pain when urinating;
  • discomfort in the pelvic area;
  • blood in the urine.

These symptoms are more often signs of prostatic hyperplasia. She is of good quality. But to exclude the risk of oncology, it is necessary to be examined by a doctor.

In some cases, the patient suffers more from manifestations of prostate cancer metastases than from the main symptoms of the disease, for example, in the later stages, the following may appear:

  • pain in bones affected by metastases (often the lower back and pelvic bones);
  • pain with compression of the spinal cord;
  • bladder dysfunction;
  • rectal dysfunction;
  • swelling of the legs due to compression of the veins and damage to the lymph nodes;
  • enlarged regional lymph nodes;
  • back pain;
  • weight loss, fatigue and drowsiness, intestinal bleeding.
Treatment of prostate cancer

Diagnosis of prostate cancer

The disease can be completely cured only in the early stages of prostate cancer, while the tumor is still small. Therefore, it is very important to get tested regularly.

The following methods are used to detect oncology:

  • Digital rectal examination (DRE) - probing through the rectum of the prostate gland, which allows you to detect lumps;
  • blood test for the presence of prostate specific antigen (PSA);
  • ultrasound examination of the prostate using a rectal probe (TRUS) inserted into the rectum, with a possible biopsy of the tumor;
  • colonoscopy;
  • Computed tomography and magnetic resonance imaging of the pelvis to assess the extent to which prostate cancer has spread to the seminal vesicles and other nearby tissues.

To verify the diagnosis, a trephine biopsy of the prostate gland is performed. To exclude distant metastases, abdominal ultrasound, skeletal scanning (osteoscintigraphy), CT or MRI of the area of interest, and X-ray examination of the lungs are performed.

The PSA blood test is widely used, but with mixed results. Normally, this level is 4 ng / ml. An increase in this level to 10 ng / ml is regarded as a 25% chance of having prostate cancer. And over 10 ng / ml - 50% probability. However, in some cases, and at a PSA level below 4 ng / ml, cancer is detected. But once a diagnosis of prostate cancer has been made, PSA tests can be used to monitor the effectiveness of treatment and assess the extent of cancer spread. So far, the first and main method for diagnosing prostate cancer is a digital rectal examination.

The TRUS procedure allows not only to diagnose and biopsy the prostate gland, but also to control the implementation of other methods of prostate cancer treatment, such as brachytherapy or cryotherapy.

Prostate cancer cell biopsy is the most accurate and reliable way to make a definitive diagnosis. For the collection of cancer cells, a puncture biopsy of the prostate gland, an ultrasound-guided biopsy with the introduction of a sensor into the rectum, and other methods can be prescribed. The biomaterial is then subjected to histological examination in the laboratory.

During the diagnosis, the task is to find out the type of tumor, the stage of prostate cancer and determine the treatment regimen. If the tumor has not had time to spread beyond the prostate, surgical removal of the prostate gland is possible, but if there are metastases, then drug therapy is indicated.

In our clinic, for the diagnosis of prostate cancer, modern equipment for hardware examinations and laboratory tests is used. During the biopsy, effective pain relief is used and the safest and least invasive methods for diagnosing prostate cancer are preferred.

Prostate cancer treatment

The choice of treatment for prostate cancer depends on the stage of the disease, the size of the tumor, and the presence of concomitant age-related diseases that may affect the possibility of surgical treatment. In the treatment of prostate cancer, one of the following methods or a combination of them is used:

  • Surgery. For prostate cancer, surgery removes the prostate itself and the tissue around it. The operation is performed in the traditional way (open), by laparoscopy (sparing operation) or using the Da Vinci robotic system. Early forms of prostate cancer are subject to surgical treatment. The surgeons of the K+31 oncology clinic are proficient in modern operating techniques that allow them to perform nerve-sparing surgeries. The clinic introduces minimally invasive prostate removal technologies, after which patients practically do not need rehabilitation measures.
  • Radiotherapy. Used in cases where surgery is contraindicated, as well as in combination with hormonal therapy, in the treatment of recurrent prostate cancer and as palliative therapy. Radiation therapy can be remote and contact. Modern methods of remote radiation therapy:
    • Three-dimensional conformal radiation therapy - consists in a directed effect from several points on the tumor, while healthy tissues are minimally affected;
    • Stereotactic therapy is a method in which the device delivers a concentrated dose of radiation to the prostate tumor, which allows you to reduce the course to days instead of weeks.
    Brachytherapy is referred to as contact radiation therapy. The radiation source is placed in the prostate gland. The method is relatively sparing, because The patient receives the maximum result with a minimum of side effects.
  • Hormonal therapy. Assign with a common process, as a palliative treatment for prostate cancer, with aggressive tumors, before a course of radiation therapy to slow down the growth of education. But after a few years, prostate cancer stops responding to therapy; enters the hormone-resistant phase. In this case, they change drugs or switch to chemotherapy.
  • Chemotherapy is possible if the tumor does not respond to hormonal drugs or if the prostate cancer has spread to distant organs.

Metastatic prostate cancer is also treatable in some cases. Radiation therapy, chemotherapy and other methods are aimed at slowing down the division of cancer cells, their destruction, even if they are in the bones or lungs.

Prostate cancer at stage I is treated with radiation therapy or radical prostatectomy (removal of the prostate gland).

Stage II prostate cancer can be treated with surgery (prostatectomy), radiation therapy, brachytherapy, or a combination of the latter.

The treatment of stage III prostate cancer, when the malignant tumor has spread to neighboring tissues, but has not yet affected the bladder and rectum, often consists in monitoring the dynamics of the tumor and controlling the disease. But treatments such as hormonal therapy, chemotherapy, radiation therapy, radical prostatectomy, transurethral resection of the prostate, as well as various combinations of these methods, can be used.

Stage 4 prostate cancer is treated with the same methods as stage 3 tumors. Basically it is a palliative treatment to reduce symptoms, reduce pain and prolong the life of the patient.

Prognosis for prostate cancer

Five-year survival rate for stage 1, 2 and even 3 prostate cancer is almost 100%. But at stage 4 prostate cancer, the prognosis drops sharply to 30% or less. True, in this case, there are quite effective methods for prolonging the life of a patient, even with prostate cancer metastases in other organs and tissues.

The ten-year survival rate after treatment for prostate cancer (namely, removal of the prostate gland) at any stage is 98%, and 15-year-old - 96%. In most cases, there is no recurrence after treatment.

Rehabilitation after surgery for prostate cancer

Recovery after prostate cancer surgery can take only a few weeks. During the operation, a catheter is placed in the bladder, which is removed after a couple of weeks. And the patient is discharged from the hospital after a few days. To prevent recurrence after surgery for prostate cancer, patients should be regularly examined and tested for PSA.

After surgical treatment of prostate cancer, there may be some consequences, for example, erectile dysfunction and infertility, urinary incontinence, a decrease in the length of the penis, inguinal hernia. But there are ways to combat these effects.

Point incontinence after prostate cancer surgery may be due to damage to the bladder sphincter, and leakage occurs during exertion (coughing, sneezing, exercise). In most cases, this goes away with time. Kegel exercises, urinals, surgical methods, and medications can help the recovery process.

Erectile dysfunction as a side effect of surgical treatment for prostate cancer is treated with drugs, implants or special vacuum devices.

Prostate cancer treatment in our K+31 clinic

For the treatment of prostate cancer in our clinic, a group of specialists of various profiles gathers, who consider the problem from all sides, take into account the patient's condition, his features. The choice of treatment method is made in the direction of the most effective and safe therapy in this particular case.

The doctors of our clinic also treat breast cancer, stomach cancer, lung cancer, liver cancer, uterine cancer, lymphoma, melanoma, as well as neoplasms of any etiology and localization. In their clinical practice, they use only proven methods for diagnosing patients and effective techniques for treating patients with a minimum of complications.

Call us by phone to make an appointment for a consultation or do it online, right on our website.

Service record



Specialists

All specialists
Merkulov
Igor Alexandrovich

Deputy chief physician for oncology, oncologist

Doctor of Sciences, PhD


Academician, professor, Doctor of Sciences, PhD

Petrov
Dmitry Yurevich

Deputy chief physician for oncology, surgeon

PhD, Docent

Ershova
Ksenia Igorevna

Head of department, oncologist

PhD

Rasner
Pavel Ilyich

Consultant in urology, urologist

Doctor of Sciences, PhD, professor

Malygin
Sergey Evgenyevich

Oncologist-mammologist, surgeon

Pshikhachev
Ahmed Mukhamedovich

Urologist, Oncologist

Doctor of Sciences, PhD

Shevchuk
Alexei Sergeyevich

Oncogynecology consultant, obstetrician-gynecologist

PhD

Chichkanova
Tatyana Vladimirovna

Oncologist-mammologist, radiologist

Katz
Ksenia Vladimirovna

Dermatovenerologist, oncologist

Rakova
Elena Sergeevna

Oncologist, chemotherapist

Udin
Oleg Ivanovich

Deputy chief physician for surgery, surgeon

PhD

Kogonia
Lali Mikhailovna

Chemotherapist

Doctor of Sciences, PhD

Ushenina
Maria Valerievna

Oncologist-chemotherapist

PhD

Stepura
Yulia Evgenievna

Head of the department of antitumor drug therapy, oncologist, chemotherapist

Volkova
Daria Mikhailovna

Head of the radiation therapy department

Gomov
Mikhail Alexandrovich

Consultant in oncogynecology, obstetrician-gynecologist

Grishin
Igor Igorevich

Obstetrician-gynecologist

Doctor of Sciences, PhD, professor

Achba
Maya Otarovna

Radiologist, ultrasound diagnostician, oncologist-mammologist